Latest Anti-obesity medication Stories
WASHINGTON, June 14, 2011 /PRNewswire-USNewswire/ -- The Obesity Care Continuum (OCC), represented by The Obesity Society (TOS), the Obesity Action Coalition (OAC), the American Society for Metabolic and Bariatric Surgery (ASMBS) and the American Dietetic Association (ADA), expresses a deep concern for the recent decision by the FDA, Division of Metabolic and Endocrinologic Products (DMEP), to require Orexigen to conduct a pre-approval cardiovascular outcomes trial for Contrave, even...
NES-ZIONA, Israel, June 13, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that the U.S. Patent and Trademark Office (PTO) has allowed a new patent for the company's veterinary version of its long-acting CTP-enhanced non-human growth hormone (NhGH-CTP). The patent covers the composition of PROLOR's proprietary pharmaceutical non-human growth hormone as well as certain associated methods of use for veterinary applications. "This new patent covering CTP-enhanced...
SAN DIEGO and SAN CARLOS, Calif., June 8, 2011 /PRNewswire/ -- Profil(TM) Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, and Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, jointly announced today a strategic alliance to offer Profil Institute customers use of Rosa's modeling technology to simulate disease physiology, drug action, patient variability,...
The drug topiramate can help people lose weight as long as they can tolerate the side effects, according to authors of a new study that reviewed the medical literature. Brazilian researchers will present the results Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.Among more than 3,300 overweight or obese patients, those who took topiramate for at least four months lost 11.8 pounds more on average than individuals who took "dummy" pills, or placebo, found the...
NES-ZIONA, Israel, June 6, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH) today reported positive results from a comparative animal study of its long-acting anti-obesity drug candidate oxyntomodulin (OXY-RPEG). The study measured the potential therapeutic effect of OXY-RPEG injected once or twice weekly as measured by weight loss and reduction in food intake compared with oxyntomodulin injected twice daily. It was conducted using a state-of-the-art animal model specifically...
OKLAHOMA CITY, June 1, 2011 /PRNewswire/ -- PE Labs has announced a new, all-natural product it says will allow users to lose weight without starving themselves, using dangerous diet drugs or scrapping their current lifestyles. The new product, called Obestrim, is said to employ a unique method for rapidly burning body fat while safely suppressing appetite for up to 12 hours with a single pill. This means users won't feel hungry or deprived while using the product, the company claims. PE...
NES-ZIONA, Israel, May 23, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that its proprietary CTP and Reversible PEGylation platforms for extending the longevity of most proteins, peptides and small molecules will be highlighted today in a presentation at the joint meeting of the Summer Neuropeptide Conference and The European Neuropeptide Club (ENC). The joint conference,...
Weight-loss groups are describing as "disturbing" a plan to give unborn babies a diet drug to stop them from being born overweight, The Telegraph is reporting. Patients at Liverpool Women's Hospital will be given the drug Metformin to reduce the food supply to their unborn babies. The treatment will not affect the weight of the mothers. Half of the patients in the study will take Metformin pills up to three times a day from 12 weeks gestation, while the other half will be given placebo drugs....
80% of Dieters Now Do It Themselves, Highest Level Ever Tampa, FL (PRWEB) May 09, 2011 Marketdata Enterprises, Inc., a leading independent market research publisher of "off-the-shelf" studies about service industries since 1979, has released its biennial 412-page study: The U.S. Weight Loss & Diet Control Market (11th edition). This is a complete analysis and forecast of ALL major segments of the U.S. diet market. "America's estimated 75 million dieters"”about 80% of whom try to...
Obesity is socially contagious, according to research published in the past few years. How it is "caught" from others remains a murky area. But findings from Arizona State University researchers published online May 5 in the American Journal of Public Health shed light on the transmission of obesity among friends and family.Shared ideas about acceptable weight or body size play only a minor role in spreading obesity among friends, according to the findings published in the article...
